8-K current report · filed Sep 3, 2026

AbbVie Inc (ABBV) 8-K Current Report: September 3, 2026

Item 7.01Item EX-99.1ABBV overview

Short answer

AbbVie Inc (ABBV) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026.

AbbVie Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • AbbVie completed its acquisition of Apogee Therapeutics on September 3, 2026
  • Strategic asset addition: Apogee pipeline includes zumilokibart (APG777) and APG273
  • Investor focus: integration execution, pipeline development, regulatory progress and commercial potential
  • Potential earnings impact tied to acquisition benefits, synergies and acquired IPR&D or milestone expenses
  • 2026 full-year and third-quarter adjusted diluted EPS guidance referenced in the announcement

Item EX-99.1 · Exhibit EX-99.1

  • Apogee acquisition completed for $135.11 per share in cash, valuing equity at approximately $10.9 billion
  • Pipeline adds late-stage zumilokibart for atopic dermatitis and APG273 for asthma, strengthening AbbVie’s immunology growth strategy
  • Acquisition expected to reduce adjusted EPS by $0.14 in 2026 and approximately $0.46 in 2027, with accretion beginning in 2032
  • 2026 adjusted EPS guidance reaffirmed at $13.87-$14.07, including the acquisition’s $0.14 dilution
  • Apogee shares ceased NASDAQ trading on Sept. 3, 2026, following transaction completion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other AbbVie Inc 8-K filings

Get the next ABBV 8-K as it lands

Follow ABBV for push alerts, or ask the research agent what this filing means.